Among people with inflammatory bowel disease, fasting during Ramadan for one month does not lead to hospital visits or changes in prescribed medications, even if some individuals experience increased symptoms.

For people with inflammatory bowel disease, following a Ramadan intermittent fasting schedule for one month does not lead to measurable changes in their quality of life or levels of depression, based on standard clinical assessments.

In people with Crohn’s disease, fasting during Ramadan does not lead to measurable changes in blood markers of inflammation or symptom severity over one month.

In people with ulcerative colitis or Crohn’s disease, fasting during Ramadan for one month does not lead to measurable changes in two biomarkers of inflammation: C-reactive protein in the blood and calprotectin in the stool.

In patients with ulcerative colitis, fasting during Ramadan for 14 to 15 hours per day is linked to a small but measurable increase in disease activity symptoms, especially in individuals aged 30 or older or those with higher baseline levels of fecal calprotectin, without corresponding changes in blood or stool markers of inflammation.

People with ulcerative colitis who fast during Ramadan may experience worse symptoms, but this is not due to increased inflammation in the body, since standard inflammation markers do not change. Other factors like changes in when medications are taken, sleep patterns, or diet may be responsible.